>
Barnaul Ammo Review: Russia's WWII Battle Buddy
Police Killed in Record Number. Alex Jones Exposes Plan to Control Police and Predicts...
75 Year Old Arizona Rancher Charged with Murder Says Migrants Pointed AK-47 at Him
WOW This Is Unbelievable. Moms Across America Meeting With The FDA
The first reverse microwave in the U.S.: you can have it at home to save energy while cooking
BREAKTHROUGH : Lightsolver Makes Ultrafast Laser Based Computers
$300,000 robotic micro-factories pump out custom-designed homes
$300,000 robotic micro-factories pump out custom-designed homes
Skynet Has Arrived: Google Follows Apple, Activates Worldwide Bluetooth LE Mesh Network
The Car Fueled Entirely by the Sun Takes Huge Step Towards Production
A new wave of wearable devices will collect a mountain on information on us...
Star Trek's Holodeck becomes reality thanks to ChatGPT and video game technology
Blazing bits transmitted 4.5 million times faster than broadband
A 13-year-old girl who was left completely bald from her alopecia has made an incredible transformation after taking an arthritis drug.
The unidentified teenager, from Brazil, had slowly been losing her hair for five years and standard medications failed to help. Doctors tried tofacitinib as a last-resort.
Tests of the drug, marketed as Xeljanz, have shown it can help alopecia patients regrow their hair – but it is not yet licensed as a conventional treatment.
After just four months, the girl regained a significant amount of her hair. She was left with thick, brown locks within two years of taking tofacitinib.
The results add to the evidence that the drug could offer hope for millions of patients around the world with alopecia, who have slim chances of making a full recovery.
Tofacitinib is routinely given to patient with rheumatoid arthritis, which is caused by inflammation. Dermatologists say the type of alopecia the girl had is caused by the same process.
Medical student Rachel Berbert Ferreira, at Centro Universitario Cesumar, was the senior author of the paper in Clinical Case Reports.